Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd (SHE:002864)
30.24
-0.07 (-0.23%)
Apr 30, 2026, 3:04 PM CST
SHE:002864 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,113 | 1,141 | 971.45 | 978.2 | 971.04 | 883.76 |
Other Revenue | - | - | 2.41 | 2.63 | 3.26 | 3.73 |
| 1,113 | 1,141 | 973.86 | 980.83 | 974.29 | 887.48 | |
Revenue Growth (YoY) | 9.79% | 17.15% | -0.71% | 0.67% | 9.78% | 32.40% |
Cost of Revenue | 534.23 | 549.08 | 381.74 | 413.74 | 408.25 | 370.36 |
Gross Profit | 578.97 | 591.79 | 592.12 | 567.09 | 566.04 | 517.12 |
Selling, General & Admin | 403.58 | 416.56 | 436.86 | 418.79 | 416.11 | 386.15 |
Research & Development | 51.89 | 53.11 | 37.54 | 20.26 | 18.23 | 14.03 |
Other Operating Expenses | -2.49 | -0.16 | 9.35 | 10.61 | 10.23 | 9.29 |
Operating Expenses | 452.98 | 469.51 | 485.59 | 453.98 | 452.94 | 414.07 |
Operating Income | 125.99 | 122.28 | 106.53 | 113.11 | 113.1 | 103.05 |
Interest Expense | - | - | -1.56 | -6.11 | -13.92 | -3.49 |
Interest & Investment Income | - | - | 25.58 | 22.06 | 17.18 | 11.78 |
Earnings From Equity Investments | -0.14 | -0.13 | - | - | - | - |
Other Non Operating Income (Expenses) | -19.31 | -13.16 | -0.22 | 0.31 | 2.55 | -5.27 |
EBT Excluding Unusual Items | 106.55 | 108.99 | 130.32 | 129.37 | 118.91 | 106.06 |
Gain (Loss) on Sale of Investments | - | - | - | -1.56 | -0.11 | - |
Gain (Loss) on Sale of Assets | 0.13 | 0.13 | -0.01 | 0.17 | - | - |
Asset Writedown | -0.35 | -0.17 | -0.18 | -0.81 | -0.08 | -0 |
Other Unusual Items | - | - | 6.82 | 2.08 | 0.46 | 2.97 |
Pretax Income | 106.32 | 108.95 | 136.95 | 129.25 | 119.18 | 109.03 |
Income Tax Expense | 19.73 | 12.93 | 17.03 | 17.7 | 16.03 | 14.47 |
Earnings From Continuing Operations | 86.59 | 96.02 | 119.92 | 111.55 | 103.15 | 94.56 |
Minority Interest in Earnings | 0.2 | 0.26 | 0.35 | -1.11 | -1.98 | -1.39 |
Net Income | 86.79 | 96.28 | 120.27 | 110.43 | 101.16 | 93.17 |
Net Income to Common | 86.79 | 96.28 | 120.27 | 110.43 | 101.16 | 93.17 |
Net Income Growth | -27.90% | -19.95% | 8.91% | 9.16% | 8.58% | 17.77% |
Shares Outstanding (Basic) | 105 | 105 | 105 | 96 | 86 | 85 |
Shares Outstanding (Diluted) | 105 | 105 | 105 | 98 | 86 | 85 |
Shares Change (YoY) | -0.15% | 0.07% | 7.02% | 13.03% | 1.16% | -0.60% |
EPS (Basic) | 0.83 | 0.92 | 1.15 | 1.15 | 1.18 | 1.09 |
EPS (Diluted) | 0.83 | 0.92 | 1.15 | 1.13 | 1.17 | 1.09 |
EPS Growth | -27.79% | -20.00% | 1.77% | -3.42% | 7.34% | 18.48% |
Free Cash Flow | 101.59 | 20.6 | 74.54 | 41.53 | 69.53 | 35.36 |
Free Cash Flow Per Share | 0.97 | 0.20 | 0.71 | 0.42 | 0.80 | 0.41 |
Dividend Per Share | - | - | 0.250 | 0.220 | 0.200 | 0.180 |
Dividend Growth | - | - | 13.64% | 10.00% | 11.11% | 20.00% |
Gross Margin | 52.01% | 51.87% | 60.80% | 57.82% | 58.10% | 58.27% |
Operating Margin | 11.32% | 10.72% | 10.94% | 11.53% | 11.61% | 11.61% |
Profit Margin | 7.80% | 8.44% | 12.35% | 11.26% | 10.38% | 10.50% |
Free Cash Flow Margin | 9.13% | 1.81% | 7.65% | 4.23% | 7.14% | 3.98% |
EBITDA | 163.39 | 158.69 | 139.02 | 142.92 | 130.16 | 117.8 |
EBITDA Margin | 14.68% | 13.91% | 14.27% | 14.57% | 13.36% | 13.27% |
D&A For EBITDA | 37.39 | 36.41 | 32.49 | 29.81 | 17.07 | 14.74 |
EBIT | 125.99 | 122.28 | 106.53 | 113.11 | 113.1 | 103.05 |
EBIT Margin | 11.32% | 10.72% | 10.94% | 11.53% | 11.61% | 11.61% |
Effective Tax Rate | 18.56% | 11.87% | 12.43% | 13.70% | 13.45% | 13.27% |
Revenue as Reported | - | - | 973.86 | 980.83 | 974.29 | 887.48 |
Advertising Expenses | - | - | 5.04 | 1.09 | 1.76 | 3.68 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.